Advertisement

Radiochemotherapy in Locally Advanced Non-Small Cell Lung Cancer

  • Branislav Jeremić
  • Aleksandar Dagović
Part of the Medical Radiology Radiation Oncology book series (MEDRAD)

Keywords

Clin Oncol Small Cell Lung Cancer Radiat Oncol Biol Phys Radiation Therapy Oncology Group Concurrent Radiochemotherapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Albain KS, Crowley JJ, Turrisi AT III, Gandara DR, Farrar WB, Clark JI, Beasley KR, Livingston RB (2002) Concurrent cisplatin, etoposide, and chest radiotherapy in pathologic stage IIIB non-small-cell lung cancer: a Southwest Oncology Group Phase II study, SWOG 9019. J Clin Oncol 20:3454–3460CrossRefPubMedGoogle Scholar
  2. Albain KS, Scott CB, Rusch VR, Turrisi AT, Shepherd FA, Smith C, Gandara DR, Johnson DH, Green MR, Miller RC (2003) Phase III comparison of concurrent chemotherapy plus radiotherapy (CT/RT) and CT/RT followed by surgical resection for stage IIIA (pN2) non-small cell lung cancer (NSCLC): initial results from intergroup trial 0139 (RTOG 93-09). Proc Am Soc Clin Oncol 21:621 (abstract 2497)Google Scholar
  3. Antonodou D, Coliarakis N, Synodinou M, Athanassiou H, Kouveli A, Verigos C, Georgakopolous G, Panousaaki K, Karageorgis P, Throuvalas N, Clinical Radiation Oncology Hellenic Group (2001) Randomized phase III trial of radiation treatment +/− amifostine in patients with advanced-stage lung cancer. Int J Radiat Oncol Biol Phys 51:915–922CrossRefPubMedGoogle Scholar
  4. Armstrong JG, Burman C, Leibel SA, Fontenla D, Kutcher G, Zelefsky M, Fuks Z (1993) Three-dimensional conformal radiation therapy may improve the therapeutic ratio of high dose radiation therapy for lung cancer. Int J Radiat Oncol Biol Phys 26:685–689PubMedGoogle Scholar
  5. Armstrong JG, Raben A, Zelefsky M, Burt M, Leibel SA, Burman C, Kutcher G, Harrison LB, Hahn C, Ginsberg R, Rusch V, Kris M, Fuks Z (1997) Promising survival with three-dimensional conformal radiation therapy for non-small cell lung cancer. Radiother Oncol 44:17–22CrossRefPubMedGoogle Scholar
  6. Arriagada R, Le Chevalier T, Rekacewicz C, Quoix E, de Cremoux H, Douillard JY, Tarayre M (1997) Cisplatin-based chemotherapy (CT) in patients with locally advanced non-small cell lung cancer (NSCLC): late analysis of a French randomized trial. Proc Am Soc Clin Oncol 16:16 (abstract)Google Scholar
  7. Ball D, Bishop J, Smith J, O'Brien P, Davis S, Ryan G, Olver I, Toner G, Walker Q, Joseph D (1999) A randomised phase III study of accelerated or standard fraction radiotherapy with or without concurrent carboplatin in inoperable non-small cell lung cancer: final report of a multi-centre trial. Radiother Oncol 52:129–136Google Scholar
  8. Belani CP, Wang W, Johnson DH, Wagner H, Schiller J, Veeder M, Mehta M. (2003) Induction chemotherapy followed by standard thoracic radiotherapy (Std.TRT) vs. hyperfractionated accelerated radiotherapy (HART) for patients with unresectable stage III A & B non-small cell lung cancer (NSCLC): phase III study of the Eastern Cooperative Oncology Group (ECOG 2597). Proc Am Soc Clin Oncol 21:622 (abstract 2500)Google Scholar
  9. Blanke C, Ansari R, Mantravadi R, Gonin R, Tokars R, Fisher W, Pennington K, O'Connor T, Rynard S, Miller M (1995) Phase III trial of thoracic irradiation with or without cisplatin for locally advanced unresectable non-small cell lung cancer: a Hoosier Oncology Group Protocol. J Clin Oncol 13:1425–1429PubMedGoogle Scholar
  10. Bonner JA, McGinnis WL, Stella PJ, Marschke RF Jr, Sloan JA, Shaw EG, Mailliard JA, Creagan ET, Ahuja RK, Johnson PA (1998) The possible advantage of hyperfractionated thoracic radiotherapy in the treatment of locally advanced non small cell lung cancer. Results of a North Central Cancer Treatment Group phase III study. Cancer 82:1037–1048CrossRefPubMedGoogle Scholar
  11. Byhardt RW (1999) Toxicities in RTOG combined-modality trials for inoperable non-small-cell lung cancer. Oncology (Huntingt) 13[Suppl 5]:116–120Google Scholar
  12. Byhardt RW, Pajak TF, Emami B, Herskovic A, Doggett RS, Olsen LA (1993) A phase I/II study to evaluate accelerated fractionation via concomitant boost for squamous, adeno, and large cell carcinoma of the lung: report of Radiation Therapy Oncology Group 84-07. Int J Radiat Oncol Biol Phys 26:459–468PubMedGoogle Scholar
  13. Byhardt RW, Scott CB, Ettinger DS, Curran WJ, Doggett RL, Coughlin C, Scarantino C, Rotman M, Emami B (1995) Concurrent hyperfractionated irradiation and chemotherapy for unresectable nonsmall cell lung cancer. Results of Radiation Therapy Oncology Group 90-15. Cancer 75:2337–2344PubMedGoogle Scholar
  14. Byhardt RW, Scott C, Sause WT, Emami B, Komaki R, Fisher B, Lee JS, Lawton C (1998) Response, toxicity, failure patterns, and survival in five Radiation Therapy Oncology Group (RTOG) trials of sequential and/or concurrent chemotherapy and radiotherapy for locally advanced non-small-cell carcinoma of the lung. Int J Radiat Oncol Biol Phys 42:469–478CrossRefPubMedGoogle Scholar
  15. Cakir S, Egehan I (2004) A randomized clinical trial of radiotherapy plus cisplatin versus radiotherapy alone in stage III non-small cell lung cancer. Lung Cancer 43:309–316CrossRefPubMedGoogle Scholar
  16. Choy H, Akerley W, Safran, Graziano S, Chung C, Williams T, Cole B, Kennedy T (1998) Multiinstitutional phase II trial of paclitaxel, carboplatin, and concurrent radiation therapy for locally advanced non-small-cell lung cancer. J Clin Oncol 16:3316–3322PubMedGoogle Scholar
  17. Choy H, DeVore RF, Hande KR, Porter LL, Rosenblatt P, Yunus F, Schlabach L, Smith C, Shyr Y, Johnson DH (2000) A Phase II study of paclitaxel, carboplatin, and hyperfractionated radiation therapy for locally advanced inopearble non-small cell lung cancer (a Vanderbilt cancer center affiliate network study). Int J Radiat Oncol Biol Phys 47:931–937CrossRefPubMedGoogle Scholar
  18. Choy H, Curran WJ, Scott CB (2002) Preliminary report of locally advanced multimodality protocol (LAMP): ACR 427: a randomized phase II study of three chemo-radiation regimens with paclitaxel, carboplatin, and thoracic radiation (TRT) for patients with locally advanced non small cell lung cancer (LA-NSCLC). Proc Am Soc Clin Oncol, 291a pp (abstract no 1160)Google Scholar
  19. Clamon G, Herndon J, Cooper R, Chang AY, Rosenman J, Green MR (1999) Radiosensitization with carboplatin for patients with unresectable stage III non-small-cell lung cancer: a phase III trial of the cancer and Leukemia group B and the Eastern Cooperative Oncology Group. J Clin Oncol 17:4–11PubMedGoogle Scholar
  20. Cox JD, Yesner R, Mietlowski W, Petrovich Z (1979) Influence of cell type on failure pattern after irradiation for locally advanced carcinoma of the lung. Cancer 44:94–98PubMedGoogle Scholar
  21. Cox JD, Azarnia N, Byhardt RW, Shin KH, Emami B, Pajak TF (1990) A randomized phase I/II trial of hyperfractionated radiation therapy with total doses of 60.0 Gy to 79.2 Gy: Possible survival benefit with > 69.6 Gy in favorable patients with Radiation Therapy Oncology Group Stage III non-small cell lung carcinoma: Report of Radiation Therapy Oncology Group 83-11. J Clin Oncol 8:1543–1555PubMedGoogle Scholar
  22. Cox JD, Pajak TF, Asbell S, Russell AH, Pederson J, Byhardt RW, Emami B, Roach M 3rd (1993) Interruptions of high-dose radiation therapy decrease long-term survival of favorable patients with unresectable non-small cell carcinoma of the lung: analysis of 1244 cases from 3 Radiation Therapy Oncology Group (RTOG) trials. Int J Radiat Oncol Biol Phys 27:493–498PubMedGoogle Scholar
  23. Crino L, Latini P, Meacci M, Corgna E, Maranzano E, Darwish S, Minotti V, Santucci A, Tonato M (1993) Induction chemotherapy plus high-dose radiotherapy versus radiotherapy alone in locally advanced unresectable non-small-cell lung cancer. Ann Oncol 4:847–851PubMedGoogle Scholar
  24. Cullen MH, Billingham LJ, Woodroffe CM, Gower N, Souhami RL, Chetiyawaedana AD, Joshi R, Rudd R, Trask C, Spiro S (1997) Mitomycin, ifosfamide and cisplatin (MIC) in non-small cell lung cancer (NSCLC) 1. Results of a randomised trial in patients with localised, inoperable disease. Lung Cancer 18[Suppl 1]:5 (abstract 10)Google Scholar
  25. Curran WJ Jr, Scott C, Langer C (2000) Phase III comparison of sequential Vs concurrent chemoradiation for pts with unresected stage III non-small cell lung cancer (NSCLC): initial report of Radiation Therapy Oncology Group (RTOG) 9410. Proc Am Soc Clin Oncol 19:484a (abstract 1891)Google Scholar
  26. Dillman RO, Seagren SL, Propert KJ, Guerra J, Eaton WL, Perry MC, Carey RW, Frei EF 3rd, Green MR (1990) A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Engl I Med 323:940–945Google Scholar
  27. Dillman RO, Herndon J, Seagren SL, Eaton WL Jr, Green MR (1996) Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of Cancer and Leukemia Group B (CALGB) 8433 trial. J Natl Cancer Inst 88:1210–1215PubMedGoogle Scholar
  28. El Sharouni SY, Kal HB, Battermann JJ (2003) Accelerated regrowth of non-small-cell lung tumors after induction chemotherapy. Br J Cancer 89:2184–2189PubMedGoogle Scholar
  29. Fukumoto S, Shirato H, Shimizu S, Ogura S, Onimaru R, Kitamura K, Yamazaki K, Miyasaka K, Nishimura M, Dosaka-Akita H (2002) Small-volume image-guided radiotherapy using hypofractionated coplanar and noncoplanar multiple fields with inoperable stage I nonsmall cell lung carcinomas. Cancer 95:1546–1553PubMedGoogle Scholar
  30. Fukuoka M, Niitani H, Suzuki A, Motomiya M, Hasegawa K, Nishiwaki Y, Kuriyama T, Ariyoshi Y, Negoro S, Masuda N (1992) Phase II study of CPT-11, a new derivative of camptothecin for previously untreated non-small cell lung cancer. J Clin Oncol 10:16–20PubMedGoogle Scholar
  31. Furuse K, Nishikawa H, Takada Y, Nishikawa H, Takada Y, Kudoh S, Katagami N, Ariyoshi Y (1999) Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 17:2692–2699PubMedGoogle Scholar
  32. Furuse K, Hosoe S, Masuda N (2000) Impact of tumor control on survival in unresectable stage III non-small cell lung cancer (NSCLC) treated with concurrent thoracic radio-therapy (TRT) and chemotherapy (CT). Proc Am Soc Clin Oncol 19 (abstract 1893)Google Scholar
  33. Gandara DR, Chansky K, Albain KS, Leigh BR, Gaspar LE, Lara PN Jr, Burris H, Gumerlock P, Kuebler JP, Bearden JD 3rd, Crowley J, Livingston R (2003) Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: phase II Southwest Oncology Group Study S9504. J Clin Oncol 21:2004–2010CrossRefPubMedGoogle Scholar
  34. Giraud P, Rosenzweig KE, Yorke E (2001) Radiotherapy for lung cancer: can IMRT decrease the risk of esophagitis? Proc Am Soc Ther Radiol Oncol (ASTRO), San Francisco, Int J Radiat Oncol Biol Phys, pp 355–356 (abstract 2250)Google Scholar
  35. Graham MV (1997) Prediciting radiation response. Int J Radiat Oncol Biol Phys 39:561–562PubMedGoogle Scholar
  36. Groen HJG, van de Leest AHW, Fokkema E, Timmer PR, Nossent GD, Smit WJ, Nabers J, Oosterhuis B, Hoekstra HJ, Hermans J, Otter R, van Putten JWG, De Vries EG, Mulder NH (2004) Phase III study of continuous carboplatin over 6 weeks with radiation versus radiation alone in stage III non small cell lung cancer. Ann Oncol 15: 427–432CrossRefPubMedGoogle Scholar
  37. Hara R, Itami J, Kondo T, Aruga T, Abe Y, Ito M, Fuse M, Shinohara D, Nagaoka T, Kobiki T (2002) Stereotactic single high dose irradiation of lung tumors under respiratory gating. Radiother Oncol 63:159–163CrossRefPubMedGoogle Scholar
  38. Herscher LL, Hahn SM, Kroog G, Pass H, Temeck B, Goldspiel B, Cook J, Mitchell JB, Liebmann J (1998) Phase I study of paclitaxel as a radiation sensitizer in the treatment of mesothelioma and non-small-cell lung cancer. J Clin Oncol 16:635–641PubMedGoogle Scholar
  39. Hof H, Herfarth K, Munter M, Hoess A, Motsch J, Wannenmacher M, Debus J (2003) Stereotactic single-dose radiotherapy of stage I non-small-cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys 56:3345–341CrossRefGoogle Scholar
  40. Holsti LR, Matson K (1980) A randomized study of split-course radiotherapy of lung cancer: long term results. Int J Radiat Oncol Biol Phys 6:977–981PubMedGoogle Scholar
  41. Jeremic B, Shibamoto Y, Acimovic L, Djuric L (1995) Randomized trial of hyperfractionated radiation therapy with or without concurrent chemotherapy for stage III non-small-cell lung cancer. J Clin Oncol 13:452–458PubMedGoogle Scholar
  42. Jeremic B, Shibamoto Y, Acimovic LJ, Milisavljevic S (1996) Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/etoposide for stage III non-small-cell lung cancer: a randomized study. J Clin Oncol 14:1065–1070PubMedGoogle Scholar
  43. Jeremic B, Shibamoto Y, Milicic B, Nikolic N, Dagovic A, Milisavljevic S (1998) Concurrent radiochemotherapy for patients with stage III non-small cell lung cancer (NSCLC). Long-term results of a phase II study. Int J Radiat Oncol Biol Phys 42:1091–1096CrossRefPubMedGoogle Scholar
  44. Jeremic B, Shibamoto Y, Acimovic LJ et al (2001) Hyperfractionated radiation therapy and concurrent low-dose, daily carboplatin/etoposide with or without week-end carboplatin/etoposide chemotherapy in stage III non-small-cell lung cancer: a randomized trial. Int J Radiat Oncol Biol Phys 50:19–25CrossRefPubMedGoogle Scholar
  45. Johnson DH, Einhorn LH, Bartolucci A, Birch R, Omura G, Perez CA, Greco FA (1990) Thoracic radiotherapy does not prolong survival in patients with locally advanced unresectable non-small cell lung cancer. Ann Intern Med 113:33–38PubMedGoogle Scholar
  46. Johnson DH, Paul DM, Hande KR, Shyr Y, Blanke C, Murphy B, Lewis M, De Vore RF 3rd (1996) Paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a phase II trial. J Clin Oncol 14:2054–2060PubMedGoogle Scholar
  47. Kelly K, Crowley J, Bunn PA Jr, Presant CA, Grevstad PK, Moinpour CM, Ramsey SD, Wozniak AJ, Weiss GR, Moore DF, Israel VK, Livingston RB, Gandara DR (2001) Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced NSCLC: a SWOG trial. J Clin Oncol 19:3210–3218PubMedGoogle Scholar
  48. Komaki R, Scott C, Ettinger D, Lee JS, Fossella FV, Curran W, Evans RF, Rubin P, Byhardt RW (1997) Randomized study of chemotherapy / radiation therapy combinations for favorable patients with locally advanced inoperable nonsmall cell lung cancer: Radiation Therapy Oncology Group (RTOG) 92-04. Int J Radiat Oncol Biol Phys 38:149–155CrossRefPubMedGoogle Scholar
  49. Komaki R, Seiferheld W, Curran W (2000) Sequential vs. concurrent chemotherapy and radiation therapy for inoperable non-small cell lung cancer (NSCLC): analysis of failures in a phase III study (RTOG 9410). Proc Am Soc Ther Radiol Oncol 42:113 (abstract 5)Google Scholar
  50. Komaki R, Lee JS, Kaplan B, Allen P, Kelly JF, Liao Z, Stevens CW, Fossella FV, Zinner R, Papadimitrakopolou V, Khuri F, Glisson B, Pisters K, Kurie J, Herbst R, Milas L, Ro J, Thames HD, Hong WK, Cox JD (2002) Randomized phase III study of chemoradiation with or without amifostine for patients with favorable performance status inoperable stage II–III non-small cell lung cancer: preliminary results. Semin Radiat Oncol 12[Suppl 1]:46–49CrossRefPubMedGoogle Scholar
  51. Kwa Sl, Lebesque JV, Theuws JC, Marks LB, Munley MT, Bentel G, Oetzel D, Spahn U, Graham MV, Drzymala RE, Purdy JA, Lichter AS, Martel MK, Ten Haken RK (1998) Radiation pneumonitis as a function of mean lung dose: an analysis of pooled data of 540 patients. Int J Radiat Oncol Biol Phys 42:1–9CrossRefPubMedGoogle Scholar
  52. Lau D, Leigh B, Gandara D, Edelman M, Morgan R, Israel V, Lara P, Wilder R, Ruy J, Doroshow J (2001) Twice-weekly paclitaxel and weekly carboplatin with concurrent thoracic radaition followed by carboplatin/paclitaxel consolidation for stage III non-small-cell lung cancer: a California Cancer Consortium phase II study. J Clin Oncol 19:442–447PubMedGoogle Scholar
  53. LeChevalier T, Arriagada R, Quoix E, Ruffie P, Martin M, Tarayre M, Lacombe-Terrier MJ, Douillard JY, Laplanche A (1991) Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: first analysis of a randomized trial in 353 patients. J Natl Cancer Inst 83:417–423PubMedGoogle Scholar
  54. LeChevalier T, Arriagada R, Tarayre M, Lacombe-Terrier MJ, Laplanche A, Quoix E, Ruffie P, Martin M, Douillard JY (1992) Significant effect of adjuvant chemotherapy on survival in locally advanced non-small cell lung carcinoma. J Natl Cancer Inst 84:58 (letter)PubMedGoogle Scholar
  55. LeChevalier T, Brisgand D, Douillard J-Y, Pujol JL, Alberola V, Monnier A, Riviere A, Lianes P, Chomy P, Cigolari S (1994) Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol 12:360–367PubMedGoogle Scholar
  56. Lee JS, Scott C, Komaki R, Fossella FV, Dundas GS, McDonald S, Byhardt RW, Curran WJ Jr (1996) Concurrent chemoradiation therapy with oral etoposide and cisplatin for locally advanced inoperable non-small-cell lung cancer: Radiation Therapy Oncology Group protocol 91-06. J Clin Oncol 14:1055–1064PubMedGoogle Scholar
  57. Leong SS, Tan EH, Fong KW, Wilder-Smith E, Ong YK, Tai BC, Chew L, Liem SH, Wee J, Foo KM, Ang P, Ang PT (2003) Randomized double-blind trial of combined modality treatment with or without amifostine in unresectable stage III non-small-cell lung cancer. J Clin Oncol 21:1767–1774CrossRefPubMedGoogle Scholar
  58. Lynch TJ Jr, Kalish L, Strauss G, Elias A, Skarin A, Shulman LN, Posner M, Frei E 3rd (1994) Phase II study of topotecan in metastatic non-small-cell lung cancer. J Clin Oncol 12:347–352PubMedGoogle Scholar
  59. Manegold C, Bergman B, Chemaissani A, Dornoff W, Drings P, Kellokumpu-Lehtinen P, Liippo K, Mattson K, van Pawel J, Ricci S, Sederholm C, Stahel RA, Wagenius G, van Walree N, ten Bokkel-Huinink W (1997) Single-agent gemcitabine versus cisplatin-etoposide: early results of a randomized phase II study in locally-advanced or metastatic non-small cell lung cancer. Ann Oncol 8:525–529CrossRefPubMedGoogle Scholar
  60. Marino P, Preatoni A, Cantoni A (1995) Randomized trials of radiotherapy alone versus combined chemotherapy and radiotherapy in stages IIIa and IIIb nonsmall cell lung cancer. A meta-analysis. Cancer 76:593–601PubMedGoogle Scholar
  61. Martel MK, Sahijdak WM, Hayman JA (1999) Incidental dose to clinically negative nodes from conformal treatment fields for nonsmall cell lung cancer. Int J Radiat Oncol Biol Phys 45:244 (abstract)CrossRefGoogle Scholar
  62. Masters GA, Haraf DJ, Hoffman PC, Drinkard LC, Krauss SA, Ferguson MK, Olak J, Samuels BL, Golomb HM, Vokes EE (1998) Phase I study of vinorelbine, cisplatin and concomitant thoracic radiation in the treatment of advanced chest malignancies. J Clin Oncol 16:2157–2163PubMedGoogle Scholar
  63. Mattson K, Holsti LR, Holsti P, Jakobsson M, Kajanti M, Liippo K, Mantyla M, Niitamo-Korhonen S, Nikkanen V, Nordman E, Platin L-H, Pyrhonen S, Romppanen M-L, Salmi R, Tammilehto L, Taskinen PJ (1988) Inoperable non-small cell lung cancer: Radiation with or without chemotherapy. Eur J Cancer Clin Oncol 24:477–482CrossRefPubMedGoogle Scholar
  64. Mauer AM, Masters GA, Haraf DJ, Hoffman PC, Watson SM, Golomb HM, Vokes EE (1998) Phase I study of docetaxel with concomitant thoracic radiation therapy. J Clin Oncol 16:159–164PubMedGoogle Scholar
  65. Millward MJ, Zalcberg J, Bishop JF, Webster LK, Zimet A, Rischin D, Toner GC, Laird J, Cosolo W, Urch M, Bruno R, Loret C, James R, Blanc C (1996) Phase I trial of docetaxel and cisplatin in previously untreated patients with advanced non-small cell lung cancer. J Clin Oncol 14: 750–758Google Scholar
  66. Morton RF, Jett JR, McGinnis WL, Earle JD, Therneau TM, Krook JE, Elliott TE, Mailliard JA, Nelimark RA, Maksymiuk AW, Drummond RG, Laurie JA, Kugler JW, Anderson RT (1991) Thoracic radiation therapy alone compared with combined chemoradiotherapy for locally unresectable non-small cell lung cancer. A randomized, phase III trial. Ann Intern Med 115:681–686PubMedGoogle Scholar
  67. Mountain CF (1986) A new international staging system for lung cancer. Chest 89:225S–233SPubMedGoogle Scholar
  68. Mountain CF (1997) Revisions in the international system for staging lung cancer. Chest 111:1710–1717PubMedGoogle Scholar
  69. Movsas B, Scott C, Langer (2003) Phase III study of amifostine in patients with locally advanced non-small cell lung cancer (NSCLC) receiving chemotherapy and hyperfractionated radiation (chemo/HFxRT): Radiation Therapy Oncology Group (RTOG) 98-01. Proc Am Soc Clin Oncol 21:636 (abstract 2559)Google Scholar
  70. Nagata Y, Negoro Y, Aoki T, Mizowaki T, Takayama K, Kokubo M, Araki N, Mitsumori M, Sasai K, Shibamoto Y, Koga S, Yano S, Hiraoka M (2002) Clinical outcomes of 3D conformal hypofractionated single high-dose radiotherapy for one or two lung tumors using a stereotactic body frame. Int J Radiat Oncol Biol Phys 52:1041–1046CrossRefPubMedGoogle Scholar
  71. Non-Small Cell Lung Cancer Collaborative Group (1995) Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Br Med J 311:899–909Google Scholar
  72. Onimaru R, Shirato H, Shimizu S, Kitamura K, Xu B, Fukumoto S, Chang T-C, Fujita K, Oita M, Miyasaka K, Nishimura M, Dosaka-Akita H (2003) Tolerance of organs at riskin small-volume, hypofractionated, image-guided radiotherapy for primary and metastatic lung cancers. Int J Radiat Oncol Biol Phys 56:126–135CrossRefPubMedGoogle Scholar
  73. Oshita F, Noda K, Nishiwaki Y, Fujita A, Kurita Y, Nakabayashi T, Tobise K, Abe S, Suzuki S, Hayashi I, Kawakami Y, Matsuda T, Tsuchiya S, Takahashi S, Tamura T, Saijo N (1997) Phase II study of irinotecan and etoposide in patients with metastatic non-small-cell lung cancer. J Clin Oncol 15:304–309PubMedGoogle Scholar
  74. Perez CA, Bauer M, Edelstein S, Gillespie BW, Birch R (1986) Impact of tumor control on survival in carcinoma of the lung treated with irradiation. Int J Radiat Oncol Biol Phys 12:539–547PubMedGoogle Scholar
  75. Perez CA, Pajak TF, Rubin P, Simpson JR, Mohiuddin M, Brady LW, Perez-Tamayo R, Rotman M (1987) Long term observations of the patterns of failure in patients with unresectable non-oat cell carcinoma of the lung treated with definitive radiotherapy. Report by the Radiation Therapy Oncology Group. Cancer 59:1874–1881PubMedGoogle Scholar
  76. Perez-Soler R, Fossella FV, Glisson BS, Lee JS, Murphy WK, Shin DM, Kemp BL, Lee JJ, Kane J, Robinson RA, Lippman SM, Kurie JM, Huber MH, Raber MN, Hong WK (1996) Phase II study of topotecan in patients with advanced non-small-cell lung cancer previously untreated with chemotherapy. J Clin Oncol 14:503–513PubMedGoogle Scholar
  77. Petrovich Z, Mietlowski W, Ohanian M, Cox J (1977) Clinical report on the treatment of locally advanced lung cancer. Cancer 40:72–77PubMedGoogle Scholar
  78. Petrovich Z, Stanley K, Cox JD, Paig C (1981) Radiotherapy in the management of locally advanced lung cancer of all cell types: final report of randomized trial. Cancer 48:1335–1340PubMedGoogle Scholar
  79. Planting A, Helle P, Drings P, Dalesio O, Kirkpatrick A, McVie G, Giaccone G (1996) A randomized study of high-dose split course radiotherapy preceded by high-dose chemotherapy versus high-dose radiotherapy only in locally advanced non-small-cell lung cancer. An EORTC Lung Cancer Cooperative Group trial. Ann Oncol 7:139–144PubMedGoogle Scholar
  80. Pritchard RS, Anthony SP (1996) Chemotherapy plus radiotherapy compared with radiotherapy alone in the treatment of locally advanced, unresectable, non-small-cell lung cancer: A meta-analysis. Ann Intern Med 125:723–729PubMedGoogle Scholar
  81. Rakowitch E, Tsao M, Ung Y, Pignol J-P, Cheung P, Chow E (2004) Comparison of the efficacy and acute toxicity of weekly versus daily chemoradiotherapy for non-small-cell lung cancer: a meta-analysis. Int J Radiat Oncol Biol 58:196–203CrossRefGoogle Scholar
  82. Reinfuss M, Glinski B, Kowalska T, Kulpa J, Zawila K, Reinfuss K, Dymek P, Herman K, Skolyszewski J (1999) Radiotherapy for stage III, inoperable, asymptomatic non-small cell lung cancer. Final results of a prospective randomized study (240 patients). Cancer Radiother 3:475–479PubMedGoogle Scholar
  83. Reynolds RD, O'Dell S (1978) Combination modality therapy in lung cancer: a survival study showing beneficial results of AMCOF (Adriamycin, Metotrexate, Cyclophosphamide, Oncobin and 5-Fluorouracil). Cancer 30:315–324Google Scholar
  84. Robertson JM, Ten Haken RK, Hazuka MB (1997) Dose escalation for non small cell lung cancer using conformal radiation therapy. Int J Radiat Oncol Biol Phys 37:1079–1085CrossRefPubMedGoogle Scholar
  85. Rosenzweig KE, Sim SE, Mychalczak B, Braban LE, Schindelheim R, Leibel SA (2001) Elective nodal irradiation in the treatment of non-small-cell lung cancer with three-dimensional conformal radiation therapy. Int J Radiat Oncol Biol Phys 50:681–685CrossRefPubMedGoogle Scholar
  86. Roswit B, Patno ME, Rapp R, Veinbergs A, Feder B, Stuhlbarg J, Reid CB (1968) The survival of patients with inoperable lung cancer: a large-scale randomized study of radiation therapy versus placebo. Radiology 90:688–697PubMedGoogle Scholar
  87. Sakai H, Yoneda S, Kobayashi K, Komagata H, Kosaihira S, Kazumoto T, Saito Y (2004) Phase II study of bi-weekly docetaxel and carboplatin with concurrent thoracic radiation therapy followed by consolidation chemotherapy with docetaxel plus carboplatin for stage III unresectable non-small cell lung cancer. Lung Cancer 43:195–201CrossRefPubMedGoogle Scholar
  88. Saunders MI, Dische S (1990) Continuous, hyperfractionated, accelerated radiotherapy (CHART) in non-small cell carcinoma of the bronchus. Int J Radiat Oncol Biol Phys 19:1211–1215PubMedGoogle Scholar
  89. Saunders M, Dische S, Barrett A, Harvey A, Griffiths G, Palmar M (1999) Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: mature data from the randomised multicentre trial. Radiother Oncol 52:137–148CrossRefPubMedGoogle Scholar
  90. Sause WT, Scott C, Taylor S, Johnson D, Livingston R, Komaki R, Emami B, Curran WJ, Byhardt RW, Turrisi AT, Dar AR, Cox JD (1995) Radiation Therapy Oncology Group 88-08 and Eastern Cooperative Oncology Group 4588: preliminary results of a phase III trial in regionally advanced, unresectable nonsmall cell lung cancer. J Natl Cancer Inst 87:198–205PubMedGoogle Scholar
  91. Sause W, Kolesar P, Taylor S IV, Johnson D, Livingston R, Komaki R, Emami B, Curran W Jr, Byhardt R, Dar AR, Turrisi A 3rd (2000) Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest 117:358–364CrossRefPubMedGoogle Scholar
  92. Schaake-Koning C, van den Bogaert W, Dalesio O, Festen J, Hoogenhout J, van Houtte P, Kirkpatrick A, Koolen M, Maat B, Nijs A (1992) Effects of concomitant cisplatin and radiotherapy on inoperable non-small cell lung cancer. N Engl J Med 326:524–530PubMedGoogle Scholar
  93. Schild SE, Stella PJ, Geyer SM, Bonner JA, Marks RS, McGinnis WL, Goetz SP, Kuross SA, Mailliard JA, Kugler MD, Schaeffer PL, Jett JR (2002) Phase III trial comparing chemotherapy plus once-daily or twice-daily radiotherapy in stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 54:370–378CrossRefPubMedGoogle Scholar
  94. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH (2002) Comparison of four chemotherapy regimens for advanced NSCLC. N Engl J Med 346:92–98CrossRefPubMedGoogle Scholar
  95. Soresi E, Borghini U, Zucali R, Leoni M, Botturi M, Vergari C, Luporini G, Scoccia S (1988) A randomized clinical trial comparing radiation therapy versus radiation therapy plus cis-Dichlorodiamine Pltinum (II) in the treatment of locally advanced non small cell lung cancer. Semin Oncol 15[Suppl 7]:20–25Google Scholar
  96. Steel GG, Peckham MJ (1979) Exploitable mechanisms in combined radiotherapy-chemotherapy. Int J Radiat Oncol Biol Phys 5:85–91Google Scholar
  97. Taylor NA, Liao ZX, Cox JD, Stevens C, Roth J, Walsh G, Chang JY, Guerrero T, Jeter M, Putnam J, Jr., Fossella FV, Allen P, Komaki R (2004) Equivalent outcome of patients with clinical stage IIIA non-small-cell lung cancer treated with concurrent chemoradiation compared with induction chemotherapy followed by surgical resection. Int J Radiat Oncol Biol Phys 58:204–212CrossRefPubMedGoogle Scholar
  98. Trovo MG, Minatel E, Franchin G, Boccieri MG, Nascimben O, Bolzicco G, Pizzi G, Torretta A, Veronesi A, Gobitti C (1992) Radiotherapy versus radiotherapy emhanced by cisplatin in stage III non small cell lung cancer. Int J Radiat Oncol Biol Phys 24:11–15PubMedGoogle Scholar
  99. Timmerman R, Papiez L, McGarry R, Likes L, DesRosiers C, Frost S, Williams M (2003) Extracranial stereotactic radioablation. Results of a phase I study in medically inoperable stage I non-small cell lung cancer. Chest 124:1946–1955CrossRefPubMedGoogle Scholar
  100. Uematsu M, Shioda A, Tahara K, Fukui T, Yamamoto F, Tsumatori G, Ozeki Y, Aoki T, Watanabe M, Kusano S (1998) Focal, high-dose, and fractionated modified stereotactic radiation therapy for lung carcinoma patients. A preliminary experience. Cancer 82:1062–1070CrossRefPubMedGoogle Scholar
  101. Ulutin HC, Pak Y (2003) Preliminary results of radiotherapy with or without weekly paclitaxel in locally advanced non-small cell lung cancer. J Cancer Res Clin Oncol 129:52–56PubMedGoogle Scholar
  102. Vokes EE, Gregor A, Turrisi AT (1998) Gemcitabine and radiation therapy for non-small cell lung cancer. Semin Oncol 25[Suppl 4]:66–69Google Scholar
  103. Vokes EE, Herndon JE II, Crawford J, Leopold KA, Perry MC, Miller AA, Green MR (2002) Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: Cancer and Leukemia Group B Study 9431. J Clin Oncol 20:4191–4198CrossRefPubMedGoogle Scholar
  104. White JE, Chen T, Reed R, Mira J, Stuckey WJ, Weatherall T, O'Bryan R, Samson MK, Seydel HG (1982) Limited squamous cell carcinoma of the lung: a Southwest Oncology Group randomised study of radiation with or without doxorubicin chemotherapy and with or without levamisole immunotherapy. Cancer Treat Rep 66:1113–1120PubMedGoogle Scholar
  105. Whyte RI, Crownover R, Murphy MJ, Martin DP, Rice TW, DeCamp MM Jr, Rodebaugh R, Weinhous MS, Le QT (2003) Stereotactic radiosurgery for lung tumors: preliminary report of a phase I trial. Ann Thorac Surg 75:1097–1101CrossRefPubMedGoogle Scholar
  106. Yorke E (2001) Advantages of IMRT for dose escalation in radiation therapy for lung cancer. Med Phys 28:1291–1294Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2005

Authors and Affiliations

  • Branislav Jeremić
    • 1
  • Aleksandar Dagović
    • 2
  1. 1.Department of Radiation Oncology, Klinikum rechts der IsarTechnische Universität MünchenMunichGermany
  2. 2.Department of OncologyUniversity HospitalKragujevacSerbia

Personalised recommendations